Tourmaline Bio (NASDAQ:TRML) Earns Buy Rating from Analysts at Chardan Capital
Stock analysts at Chardan Capital began coverage on shares of Tourmaline Bio (NASDAQ:TRML – Get Free Report) in a report issued on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 304.16% from the company’s current price. […]
Stock analysts at Chardan Capital began coverage on shares of Tourmaline Bio (NASDAQ:TRML – Get Free Report) in a report issued on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 304.16% from the company’s current price. […]
